Sema4 Closes Transaction with CM Life Sciences, Debuts as Publicly Traded AI-driven Genomic & Clinical Data Platform CompanyGlobeNewsWire • 07/22/21
Former Magenta Therapeutics and Foundation Medicine CFO Jason Ryan to Join Sema4 Board of DirectorsBusiness Wire • 07/07/21
CM Life Sciences and Sema4 Announce Release of Definitive Proxy Statement for July 21 Shareholder Meeting to Vote on Business CombinationBusiness Wire • 07/02/21
Sema4 Appoints Andrew Kasarskis, Health Data Expert and Precision Medicine Scientist, as Chief Data OfficerBusiness Wire • 06/17/21
Sema4 and CM Life Sciences Announce the Filing of Amended Preliminary Proxy StatementBusiness Wire • 06/10/21
AdventHealth and Sema4 Launch a Data-driven Precision Medicine Program to Optimize Patient Care and OutcomesBusiness Wire • 05/25/21
Sema4 and CM Life Sciences Announce the Filing of the Schedule-14A Proxy Statement in Connection with the Proposed MergerBusiness Wire • 05/06/21
CM Life Sciences Announces Filing of Amended Annual Report on Form 10-K Relating to Restatement of Financial Statements in Accordance with Recent SEC GuidanceBusiness Wire • 05/05/21
INVESTIGATION ALERT: Halper Sadeh LLP Investigates QELL, CMLF, AJAX, BOWX, SV; Shareholders are Encouraged to Contact the FirmPRNewsWire • 04/29/21
NorthShore and Sema4 Launch System-Wide Genomics Program to Improve Primary and Specialty Care with Data-Driven InsightsBusiness Wire • 04/19/21
CM Life Sciences II: SomaLogic Is Great, But Post-Merger SPAC Dilution Should Frighten InvestorsSeeking Alpha • 04/01/21
CM Life Sciences: SPAC Acquires Sema4, A Promising AI Health Intelligence Co.Seeking Alpha • 02/23/21
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of CM Life Sciences, Inc. - CMLFPRNewsWire • 02/13/21
CMLF Stock: 13 Things to Know About CM Life Sciences and the Sema4 SPAC MergerInvestorPlace • 02/10/21
Sema4, a Disruptive AI-driven Genomic & Clinical Data Platform Company, to Combine with CM Life Sciences to Accelerate GrowthBusiness Wire • 02/10/21